AstraZeneca´s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials
(World News Science)

CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two ora ......